Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$5.61 USD
+0.14 (2.56%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $5.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
AUPH 5.61 +0.14(2.56%)
Will AUPH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AUPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AUPH
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
AUPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for AUPH
Aurinia to Participate in Upcoming Investor Healthcare Conferences
Aurinia Announces 2024 Annual General Meeting Results
Aurinia Pharmaceuticals AGM Shareholder Decisions
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
Aurinia’s LUPKYNIS Shows Promise for Lupus Nephritis